Navigation Links
Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
Date:5/6/2009

- Favorable results for secondary endpoints support outcomes benefit

HAYWARD, Calif., May 6 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation Suppression), a clinical trial designed to examine the impact of 500mg of varespladib when administered to patients within 96 hours of an Acute Coronary Syndrome (ACS) event, met its primary endpoint of a reduction in Low Density Lipoprotein Cholesterol (LDL-C). All patients in the FRANCIS trial received once daily doses of 80mg of Lipitor (atorvastatin calcium), plus 500mg of varespladib or matching placebo. Varespladib is a potent and highly selective oral inhibitor of secretory phospholipase A2 (sPLA2), an inflammatory enzyme implicated in ACS, vascular inflammation, atherosclerosis and adverse lipid profiles.

The pre-specified primary endpoint analysis was conducted when 500 patients reached at least eight weeks of treatment after an ACS event. In addition to meeting the primary endpoint, additional efficacy analyses at a variety of time points showed positive results for all clinically important secondary endpoints. The initial data review demonstrated:

- A statistically significant reduction in LDL-C at all prospectively defined time points and statistically significant reductions in total cholesterol and non-HDL cholesterol

- Varespladib's immediate and selective inhibition of sPLA2 effectively suppressed inflammation following the index event and was further evidenced by a statistically significant reduction in C-reactive protein.

- A statistically significant greater proportion of patients treated with varespladib achieved LDL-C levels of 70mg/dL or less (a target established by the American Treatment Program III for high-r
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
2. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
3. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
4. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
5. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
6. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
7. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
8. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
9. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
10. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
11. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...PRNewswire/--Reportlinker.comannouncesthatanewmark...UnitedStatesDentalDevicesMarketAnalysisandForecast...33/United-States-Dental-Devices-Market-Analysis-an...DevicesMarketAnalysisandForecaststo2015 ,, Sum...thinformationanddatarelatingtotheUSdentaldevicesma...
(Date:11/25/2009)....,Nov.25/PRNewswire-FirstCall/--Abaxis,Inc.(Nasdaq...-of-carebloodanalysissystems,announcedtodaythatCli...esentatthe21stAnnualPiperJaffrayHealthCareConferen...encewillbeheldattheNewYorkPalaceHotelinNewYorkCity...turesandmarketsportablebloodanalysissystemsforusei...
(Date:11/25/2009)...ov.25/PRNewswire/--AccordingtoMillenniumResearchGr...etintelligence,thenearly$3billionUSmarketfortrauma...nextfiveyearsdespitetherecenteconomicslowdown.MRG,...hismarketwillremainhighlydynamicoverthenextfiveyea...reviouslyunderservedsegmentsofthetraumafixationmar...
Breaking Medicine Technology:Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3Quest Diagnostics Marks Sixth Year on Dow Jones Sustainability Index 56259 1Quest Diagnostics Marks Sixth Year on Dow Jones Sustainability Index 56259 2Swine Flu Vaccine Seems Safe 3A Experts 56255 1Swine Flu Vaccine Seems Safe 3A Experts 56255 2Swine Flu Vaccine Seems Safe 3A Experts 56255 3Nurses and Retirement Security 3A A Looming Crisis 3F 56253 1Nurses and Retirement Security 3A A Looming Crisis 3F 56253 2Nurses and Retirement Security 3A A Looming Crisis 3F 56253 3
(Date:11/26/2009)...al rollercoaster, study finds , , THURSD...actor meets the jubilant sports fan. , A new st...ho root for the winning team -- enjoy the greatest...d victory was in doubt, producing feelings of worr...iving weekend as you,re glued to the TV set, watch...
(Date:11/26/2009)...ions announces a highly effective and unconvention... to make an economic recovery. , ...the type of challenge that could send ailing holid...avid Benton, business growth expert and author of ... The Rfactor Intensive . “Fear is one of t...
(Date:11/25/2009)...-FirstCall/-- OnyxPharmaceuticals,Inc.(Nasdaq: ON...reventsinDecember: ,, ASHBriefing ,, D...ipalinvestigatorswilldiscussdatapresentationssurro...emyeloma,asfeaturedatthe51stAmericanSocietyofHemat...A.Theteleconferencewillbeginat9:00a.m.CT/10:00a.m....
(Date:11/25/2009)...USNewswire/--AnarticlebyJanetWoodcock,M.D.,directo...ed"ADifficultBalance-PainManagement,DrugSafety,and...dJournalofMedicine. ,, (Logo: http://www.newsco...rticle,WoodcockdiscussesFDAeffortstostrikeabalance...anagingtherisksposedbyvariousanalgesics.Asexamples...
(Date:11/25/2009)...who were treated with cisplatin-based chemotherapy...cal side effects and Raynaud-like phenomena, than ...ing to a new study published online November 25 in..., Marianne Brydy, M.D., of the Department of Onco...rway, and colleagues conducted a cross-sectional s...
Breaking Medicine News(10 mins):Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...is caused by the enterotoxin produced by the bacte...ng and watery diarrhea. A recent outbreak of chole...using seven deaths and more than 150 patients are ...ions where treatment is not given. The Health mini...
...ers at the University of Pittsburgh have demonstra...in mouse cells leads to dramatic chromosomal insta...bject to environmental, chemical and cellular impa...ymes to make needed repairs to genes in time can l...
... Health Minister, Andy Kerr has urged to increase ...le as it could save lot of human loss dying // du...onors. Organ failure of heart and liver causes hea...with NHS organ donor register, which would help in...
...an specialists say that some skin cancer clinics a... are harmless, but miss some genuine // melanoma... say that some cases have had questionable procedu...at it is a spin-off of the "GPs versus specialists...
...conducted in the US has revealed that seeing adver...start drinking. The UK has one // of the highest...ith nearly 20% of those aged between 11 and 15 yea...been able to establish whether there was a causal ...
...stralian study it has been revealed that every fou...e treatment from there doctors and risking their h...become so popular that half the population practic...bstetrics and gynaecology department Professor Ala...
Other Medicine News:Health News:Little Known DNA Repair Enzyme May Be A Tumor Suppressor Gene 2Health News:Little Known DNA Repair Enzyme May Be A Tumor Suppressor Gene 3
K1 Standard Keratometer
Replacement Bulb: XBO 150W/CR OFR
Replacement Bulb: XBO 100W/OFR
Replacement Bulb: XBO 75W/2
Medicine Products: